Atessia
Atessia is a French regulatory and pharmaceutical affairs consultancy serving pharmaceutical, biotech, and medical device companies with strategy, marketing authorization, vigilance, audit, and regulatory monitoring services across six offices in France and Luxembourg.
- Company typePrivate
- Founded2017
- HeadquartersParis, France
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Atessia does
Atessia is a privately held French regulatory and pharmaceutical affairs consultancy headquartered in Paris (3, rue d'Uzès, 75002) and operating across six locations including Lyon, Luxembourg, Nice, Bordeaux, and Lille. Founded in 2017 by Géraldine Baudot-Visser, a Doctor of Pharmacy, the firm serves pharmaceutical, biotechnology, and medical device companies requiring specialized expertise in European and French regulatory frameworks (EMA, ANSM, MDR), and is led day-to-day by CEO Fabrice Marinier.
The firm's service portfolio covers the full medicines lifecycle — regulatory and pharmaceutical strategy, R&D consulting, marketing authorization drafting and submission, post-MA lifecycle management, audits, quality management system creation and maintenance, and pharmacovigilance — plus medical device regulatory affairs added in 2023. The group structure includes the Atessia Intelligence subscription platform (115 subscribers for personalized regulatory monitoring), Atessia Master Class training (QUALIOPI-certified), the Atessia Vigilances subsidiary for health vigilance, and Amarylys for consultant resource outsourcing, all unified under the Atessia & Co umbrella.
Atessia's business model is a hybrid of professional services consulting (custom-priced engagements), recurring subscription revenue (Atessia Intelligence), and certified training (Atessia Master Class). The firm holds ISO 9001:2015 certification from AFNOR — claiming first-mover status in its niche — alongside the EMA PME label, CIR research tax credit accreditation, and Great Place To Work 2025-2026 recognition, and has executed high-profile work including regulatory due diligence for BC Partners on the July 2025 acquisition of Biogaran.
Atessia firmographics
Firmographics- Name
- Atessia
- Legal name
- ATESSIA SAS
- Website
- https://atessia.fr
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Atessia is a French regulatory and pharmaceutical affairs consultancy serving pharmaceutical, biotech, and medical device companies with strategy, marketing authorization, vigilance, audit, and regulatory monitoring services across six offices in France and Luxembourg.
- Ownership category
- akta.pro rank
Where Atessia is headquartered
LocationHeadquarters
- HQ city
- Paris
- HQ country
- France
- HQ region
- Europe
Offices6 records
Markets served
Atessia business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
Revenue model
- Regulatory and Pharmaceutical Consulting: Professional consulting services providing expertise in regulatory affairs, pharmaceutical strategy, quality management, pharmacovigilance, and regulatory monitoring for the health industries including medicines and medical devices.
- Atessia Intelligence Subscription: Subscription-based regulatory intelligence service offering personalized regulatory monitoring and updates to subscribers in the health industry.
- Training Services: Intra-company training services (Atessia Master Class) certified under QUALIOPI, providing professional development in regulatory and pharmaceutical affairs.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels5 records
Atessia product offering
Product offeringCore offering
Atessia is a regulatory and pharmaceutical affairs consultancy that supports health industry clients across complex, disruptive, and scalable projects. The firm offers tailormade consulting services covering regulatory strategy, research and development, marketing authorisation, quality management, pharmacovigilance, audits, and medical device regulatory affairs. It also operates Atessia Intelligence, a subscription-based regulatory monitoring service for medicines and medical devices, and Atessia Master Class for certified professional training.
Product overview
Atessia is a regulatory and pharmaceutical affairs consultancy (Life Science Advisors) serving the health industries. The company operates a portfolio of interconnected services organized around medicines and medical devices. Core offerings include Regulatory & Pharmaceutical Strategy, Research & Development Consulting, Marketing Authorisation Services, and Medical Devices Regulatory Affairs. The company differentiates through Atessia Intelligence, a subscription-based regulatory monitoring service, and operates subsidiary companies including Atessia Vigilances (health vigilance specialization) and Amarylys (consultant resource outsourcing). Additional services include audits, quality management, pharmacovigilance, and Atessia Master Class professional training programs.
Differentiator
Problem solved
Functional benefit
Brands
- Atessia Intelligence: Regulatory intelligence subscription service providing subscribers with personalized regulatory monitoring and updates
- Atessia Vigilances
- Atessia Master Class
- Atessia & Co
Products and services
- Regulatory & Pharmaceutical Strategy
- Research & Development Consulting
- Marketing Authorisation Services
- Medical Devices Regulatory Affairs
- Medicines – Exploitant Services
- Audits
- Regulatory Monitoring
- Atessia Intelligence
- Atessia Master Class Training
Quantifiable outcome
- 115 subscribers to Atessia Intelligence regulatory monitoring service
- +1 more outcomes
Companies that use Atessia
Customer profileNamed customers4 records
Segments5 records
Ideal customer profiles4 records
Atessia technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Atessia partnerships and signals
Strategic signalPartnerships
Nine partnerships are on record, tiered minor, flagship and core.
- VIGIPHARMminorCo-organized training workshop on regulatory impacts of MDR (Medical Device Regulation) on material vigilance, held in Paris.
- UBAQflagshipStrategic collaboration defining a new standard to facilitate regulatory management challenges for health sector actors. Joint innovation in regulatory affairs combining Atessia's pharmaceutical expertise with UBAQ's capabilities.
- Buzz e-santéminorLunchwork partnership on emerging digital channels and regulatory framework for pharmaceutical laboratories.
- LexCaseminorPartnership on French early access reform (accès précoce) analysis webinar, organized around lunch time.
- CAPE-Expert & LutessaminorJoint webinar on Exploitant Information Systems (Système d'information de l'Exploitant), attended by over 80 participants.
- FieldfisherminorWebinar collaboration on 'anti-gift' regulatory provisions in the pharmaceutical sector.
- Tekila Conseil (Valérie Buc-Manfré)minorAfterwork VIP event on pharmaceutical establishment operator (Exploitant) experience with ANSM injunctions.
- AmarylyscoreResource outsourcing company within the Atessia & Co group, designed to meet customers' needs for consultants in Regulatory and Pharmaceutical Affairs. Amarylys represents a sister company for workforce augmentation.
- Atessia VigilancescoreCompany specializing in health vigilance, providing expertise and support on specific regulatory and operational issues in pharmacovigilance and material vigilance.
Scale indicators4 records
Recent moves10 records
Expansion highlights6 records
Atessia competitors and assessment
Company assessmentMarket position
Competitive moat5 records
Customer concentration
Atessia social profiles
Digital presenceAtessia compliance and trust
Trust signalCompliance10 records
Atessia financial estimates
Financial estimateRevenue estimate
Valuation estimate
Atessia leadership team
Management profileNumber of profiles
Profiles5 records
Atessia subsidiaries and ownership
Company hierarchySubsidiaries2 records
Atessia funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Atessia M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Atessia
What does Atessia do?
Atessia is a regulatory and pharmaceutical affairs consultancy that supports health industry clients across complex, disruptive, and scalable projects. The firm offers tailormade consulting services covering regulatory strategy, research and development, marketing authorisation, quality management, pharmacovigilance, audits, and medical device regulatory affairs. It also operates Atessia Intelligence, a subscription-based regulatory monitoring service for medicines and medical devices, and Atessia Master Class for certified professional training.
Is Atessia a public or private company?
Atessia is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Atessia founded?
Atessia was founded in 2017. It employs 11 to 50 people.
Where is Atessia based?
Atessia is headquartered in Paris, France, in the Europe region.
How does Atessia make money?
Three revenue lines are on record. Regulatory and Pharmaceutical Consulting is the primary driver. The others are atessia Intelligence Subscription and training Services.
Does Atessia have an API?
No public API is recorded for Atessia.